Orencia(abatacept)
Orencia (abatacept) is a protein pharmaceutical. Abatacept was first approved as Orencia on 2005-12-23. It is used to treat juvenile arthritis, psoriatic arthritis, and rheumatoid arthritis in the USA. It has been approved in Europe to treat juvenile arthritis, psoriatic arthritis, and rheumatoid arthritis. The pharmaceutical is active against T-lymphocyte activation antigen CD80 and T-lymphocyte activation antigen CD86.
Download report
Favorite
BMS
Commercial
Trade Name
FDA
EMA
Orencia
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Abatacept
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Orencia | abatacept | Bristol-Myers Squibb Company | N-125118 RX | 2005-12-23 | 5 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| orencia | Biologic Licensing Application | 2020-06-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| juvenile arthritis | EFO_0002609 | D001171 | M08 |
| psoriatic arthritis | EFO_0003778 | D015535 | L40.5 |
| rheumatoid arthritis | EFO_0000685 | D001172 | M06.9 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
abatacept, Orencia, Bristol-Myers Squibb Company | |||
| 2028-12-15 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
Clinical
Clinical Trials
191 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 9 | 13 | 31 | 21 | 18 | 88 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | 1 | 2 | 1 | — | 4 |
| Dermatomyositis | D003882 | EFO_0000398 | M33 | 1 | 1 | 1 | 1 | — | 4 |
| Rheumatic diseases | D012216 | M79.0 | — | — | — | 1 | — | 1 | |
| Biliary liver cirrhosis | D008105 | K74.3 | — | — | — | 1 | — | 1 | |
| Spondylarthritis | D025241 | — | — | — | 1 | — | 1 | ||
| Pemphigus | D010392 | EFO_1000749 | L10 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | 2 | 7 | 1 | — | — | 7 |
| Juvenile arthritis | D001171 | EFO_0002609 | M08 | — | — | 4 | — | — | 4 |
| Lupus nephritis | D008181 | EFO_0005761 | 2 | 2 | 1 | — | — | 4 | |
| Covid-19 | D000086382 | U07.1 | 1 | 2 | 1 | — | — | 3 | |
| Giant cell arteritis | D013700 | EFO_1001209 | M31.6 | — | 1 | 2 | — | — | 3 |
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | — | 1 | 2 | — | — | 3 |
| Granulomatosis with polyangiitis | D014890 | EFO_0005297 | M31.3 | 1 | 2 | 1 | — | — | 3 |
| Anti-neutrophil cytoplasmic antibody-associated vasculitis | D056648 | I77.82 | — | 2 | 1 | — | — | 3 | |
| Neoplasms | D009369 | C80 | — | 1 | 1 | — | — | 2 | |
| Myelodysplastic syndromes | D009190 | D46 | — | 1 | 1 | — | — | 2 |
Show 13 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft vs host disease | D006086 | D89.81 | 4 | 7 | — | — | — | 8 | |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 4 | — | — | — | 5 |
| Psoriasis | D011565 | EFO_0000676 | L40 | 2 | 2 | — | — | — | 4 |
| Interstitial lung diseases | D017563 | EFO_0004244 | J84.89 | — | 3 | — | — | — | 3 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | — | 2 | — | — | — | 2 |
| Diffuse scleroderma | D045743 | EFO_0000404 | 1 | 2 | — | — | — | 2 | |
| Alopecia areata | D000506 | EFO_0004192 | L63 | — | 2 | — | — | — | 2 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | 1 | 1 | — | — | — | 2 | |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | 1 | — | — | — | 2 |
| Eye diseases | D005128 | EFO_0003966 | H44 | — | 1 | — | — | — | 1 |
Show 18 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 2 | — | — | — | — | 2 |
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 | ||
| Mucopolysaccharidosis i | D008059 | E76.0 | 1 | — | — | — | — | 1 | |
| Aplastic anemia | D000741 | HP_0001915 | D61.9 | 1 | — | — | — | — | 1 |
| Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | 1 | — | — | — | — | 1 |
| Wiskott-aldrich syndrome | D014923 | D82.0 | 1 | — | — | — | — | 1 | |
| Hemophagocytic lymphohistiocytosis | D051359 | D76.1 | 1 | — | — | — | — | 1 | |
| Diamond-blackfan anemia | D029503 | D61.01 | 1 | — | — | — | — | 1 | |
| Shwachman-diamond syndrome | D000081003 | 1 | — | — | — | — | 1 | ||
| Fanconi anemia | D005199 | Orphanet_84 | D61.09 | 1 | — | — | — | — | 1 |
Show 12 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis b | D019694 | EFO_0004197 | B18.1 | — | — | — | — | 1 | 1 |
| Gaucher disease | D005776 | Orphanet_355 | E75.22 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ABATACEPT |
| INN | abatacept |
| Description | 1-25-oncostatin M (human precursor) fusion protein with CTLA-4 (antigen) (human) fusion protein with immunoglobulin G1 (human heavy chain fragment), bimolecular (146-146')-disulfide |
| Classification | Protein |
| Drug class | receptor molecules or membrane ligands, natural, modified or modified: T-cell receptors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 332348-12-6 |
| RxCUI | 614391 |
| ChEMBL ID | CHEMBL1201823 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB01281 |
| UNII ID | 7D0YB67S97 (ChemIDplus, GSRS) |
Target
Agency Approved
CD80
CD80
CD86
CD86
Organism
Homo sapiens
Gene name
CD80
Gene synonyms
CD28LG, CD28LG1, LAB7
NCBI Gene ID
Protein name
T-lymphocyte activation antigen CD80
Protein synonyms
Activation B7-1 antigen, B-lymphocyte activation antigen B7, B7, BB1, CD80, CD80 antigen (CD28 antigen ligand 1, B7-1 antigen), costimulatory factor CD80, costimulatory molecule variant IgV-CD80, CTLA-4 counter-receptor B7.1
Uniprot ID
Mouse ortholog
Cd80 (12519)
T-lymphocyte activation antigen CD80 (Q61332)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Orencia - Bristol Myers Squibb
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,903 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15,232,166 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more